Aim: To observe the disabled degree improvement of acute cerebral patients treated by the combination of small-dose aspirin plus lumbrukinase versus ordinary dose of aspirin. Methods: Totally 117 first-episode patients with acute cerebral thrombosis in internal carotid artery were selected from the Department of Neurology, Xuanwu Hospital of the Capital University of Medical Sciences between March and October 2005, and divided into 2 groups at random. Besides the routine basic treatment, two lumbrukinase enteric-coated capsules (600 000 U once, three times a day, taken 30 minutes before meals) and aspirin enteric-coated tablets (40 mg once a day) were given to all the 58 cases in the experimental group, while only aspirin enteric-coated tablets (100 mg once a day) were given to all the 59 cases in the control group. All the subjects were treated for a course of 28 days. After 14 and 28 days, the changes of platelet aggregation rate and plasma fibrinogen (FG) content were detected with multifunctional double-passage blood coagulation apparatus and automatic blood coagulation apparatus respectively, and compared between the 2 groups. The changes of neurological deficit score and disabled level (Barthel index score) were also compared. The neurological deficit score was taken as the judged standard of curative effect: reduced 90%-100% as almost recovery, reduced 46%-90% as significant improvement; reduced 18%-45% as improvement, reduced less than 18% or increased more than 18% as inefficiency. The total clinic efficiency is the summation of the patients who had almost recovery or significant improvement. Results: There were 5 cases excluded in the experimental group (2 of progressive stroke at the second day of medication, 3 automatically left) and 7 in the control group (1 of coronary atherosclerotic heart disease, 3 of progressive stroke at 2-4 days after medication, 3 automatically left). Totally the 53 cases in experimental group and 52 controls were involved in the result analysis. 1 After 14-day treatment, the total effective rate was significantly higher in experimental group than in control group (77%, 58%, χ2=6.440, P < 0.05). The neurological deficit score was significantly lower in experimental group than in control group [(13.51±7.06), (16.24±6.45), t=2.378, P < 0.05]. 2 After 28-day treatment, the level of disabled improvement in experimental group was much higher than that in control group[(68.28 ±26.41), (61.51 ± 26.33), t=2.637, P < 0.05]. 3 After 14-day and 28-day treatments, the content of plasm FB in the experimental group was significantly lower than that before treatment,[(3.52±1.73), (4.25±2.01) g/L, t=2.346, P < 0.05]; [(3.45±1.67), (4.25±2.01) g/L, t=2.456, P < 0.05], with the significant difference, however there were no changes in FB content in the control group(P > 0.05). 4 There was no difference in the platelet aggregation rate between the 2 groups after 14-day and 28-day treatments (P > 0.05). Conclusion: No difference was found in platelet aggregation rate between small-dose aspirin plus lumbrukinase and large dose of aspirin, and the former could decrease the FB content and disable.